Baird reiterates Immunocore stock rating on combination therapy data
Baird maintained an Outperform rating and $84.00 price target for Immunocore (IMCR), citing positive Phase 1/2 data for a combination therapy in uveal melanoma. The stock trades at $29.13, with analysts noting potential undervaluation. IMCR reported $429M revenue over the last year, with 13% growth but no profitability. Five analysts revised earnings upwards.
How this was made
The 30-second read
Why it matters
The main tradable element is the reiterated rating plus a specific $84 price target, justified by durability improvements versus monotherapy in first-line uveal melanoma and supportive cutaneous melanoma monotherapy/combination rationale.
Market read
For IMCR, the note can support near-term sentiment and positioning, but it is not a new clinical filing or regulatory decision.
What to watch
The article notes IMCR remains unprofitable; traders may discount upside until profitability path, larger trial readouts, or regulatory milestones de-risk the program.
Background
Baird’s note reiterates a bullish stance on Immunocore’s melanoma combination approach, referencing SITC-presented Phase 1/2 results.
Ticker impact
Baird reiterated an Outperform rating and $84 price target for Immunocore, citing SITC Phase 1/2 data where Kimmtrak plus brenetafusp showed greater durability than monotherapy in first-line uveal melanoma.
Likely upward bias as traders price in continued confidence in the combination regimen and the reiterated higher target.
The article is an analyst reiteration, but it anchors the thesis to specific clinical durability data and a fresh price-target number, which can move sentiment even without new company filings.
Market effects
Reinforces positive sentiment toward oncology immunotherapy combination strategies and melanoma franchise durability narratives.
No clear regional spillover beyond US biotech sentiment.
Limited, as the catalyst is company-specific clinical data and a US analyst note.
Counterpoint
Combination-therapy durability from early Phase 1/2 data may not translate into definitive efficacy, safety, and regulatory outcomes, so the target could be overly optimistic.
Key entities
- companyImmunocore Holdings
NASDAQ-listed biotech focused on immunotherapy, subject of the analyst reiteration tied to SITC clinical data.
- analyst_firmBaird
Brokerage reiterating Outperform and $84 price target for IMCR.
- productKimmtrak
Immunocore therapy referenced as monotherapy and in combination with brenetafusp.
- productbrenetafusp
Combination partner referenced in Phase 1/2 durability comparisons.
- conferenceSITC
Conference where the Phase 1/2 combination therapy data were presented.
